Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.

doi:10.1371/journal.pone.0081068

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.

PloS one - 1 Jan 2013

Wei Siau Jia, Joseph Thomas, Chee Sharon, Li Ling, Yurlova Larisa, Zolghadr Kourosh, Brown Christopher, Lane David, Verma Chandra, Ghadessy Farid

Abstract excerpt

Pharmacological modulation of p53 activity is an attractive therapeutic strategy in cancers with wild-type p53. Presently in clinical trials, the small molecule Nutlin-3A competitively binds to HDM2, a key negative regulator of p53 and blocks its activity. We have described resistance mutations in HDM2 that selectively reduce affinity for Nutlin but not p53. In the present communication, we show that stapled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Knockout Techniques
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ligands

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Piperazines

Share to Protein Interaction Domains and Motifs

Share to Proto-Oncogene Proteins c-mdm2

Source

Open in PubMed Open full text

Identifiers

PMID: 24278380
DOI: 10.1371/journal.pone.0081068
PMCID: PMC3835680

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.